Global /Taiwan /Healthcare /Drug Manufacturers - General /3176

Medigen Biotechnology Corp.

3176

• TPEX: 3176 • Delayed

32.95TWD -2.1%

1.04 USD

As of 6 June 2026, Medigen Biotechnology Corp. has a market cap of $149.02M USD, ranking #22919 globally and #1137 in Taiwan. It ranks #2064 in the Healthcare sector, and #743 in the Drug Manufacturers - General industry.

Global Rank

22919

Country Rank

1137

Sector Rank

2064

Industry Rank

743

Key Stats

Market Cap

$149.02MUSD

4.69B TWD

Enterprise Value

$198.78MUSD

6.28B TWD

Revenue (TTM)

$50.31MUSD

1.58B TWD

EBITDA (TTM)

-$283.13KUSD

-8.95M TWD

Net Income (TTM)

-$3.46MUSD

-108.8M TWD

EBITDA Margin

-0.6%

Profit Margin

-6.9%

PS Ratio

3.0

PB Ratio

1.0

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Shun-Lang Chang open_in_new

Founded

1990

Website

medigen.com.tw open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.1%	10%	2.3%	0.6%	12%	1.7%	12%	-4.1%	-49%

News

Markets

Exchange	Ticker	Price	Quotes
Taipei Exchange (TPEX) MIC: ROCO PRIMARY	3176 基亞生物科技股份有限公司 ISIN: TW0003176004 Shares Out.: Shares Outstanding: 139.307M¹ Shares Float: 108.414M² TV: TradingView: TPEX: 3176 SA: Stock Analysis: TPEX: 3176 YF: Yahoo Finance: 3176.TWO GF: Google Finance: TPEX: 3176 BA: Barron's: 3176 MS: Morningstar: ROCO: 3176	32.95 TWD	TV: TradingView: TPEX: 3176 SA: Stock Analysis: TPEX: 3176 YF: Yahoo Finance: 3176.TWO GF: Google Finance: TPEX: 3176 BA: Barron's: 3176 MS: Morningstar: ROCO: 3176

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Medigen Biotechnology Corp.

Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for head and neck cancer, and gastric cancer patients in the United States. Medigen Biotechnology Corp. was founded in 1990 and is headquartered in Taipei, Taiwan.

Similar Companies

Industry: Drug Manufacturers - General (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
PharmaEssentia Corp. TWSE: 6446	$7.8B 245.34B TWD 5K%	48.6	Taiwan
Lotus Pharmaceutical Co., Ltd. TWSE: 1795	$1.84B 57.95B TWD 1K%	12.2	Taiwan
Center Laboratories, Inc. TPEX: 4123	$925.55M 29.11B TWD 521%	3.4	Taiwan
Lumosa Therapeutics Co., Ltd. TPEX: 6535	$809.3M 25.46B TWD 443%	-	Taiwan
Oneness Biotech Co., Ltd. TPEX: 4743	$789.12M 24.82B TWD 430%	-	Taiwan
TTY Biopharm Company Ltd. TPEX: 4105	$584.14M 18.38B TWD 292%	11.8	Taiwan

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 511K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 367K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 242K%	97.4	United States
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 218K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 194K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 186K%	20.5	Switzerland

chevron_leftBack